Glycopyrronium tosylate

Chemical compound

US DailyMed: Glycopyrronium

Routes of
administrationTopicalDrug classMuscarinic antagonistATC code

D11AA01 (WHO)

Legal statusLegal status

US: ℞-only^[1]
In general: ℞ (Prescription only)

IdentifiersCAS Number

1624259-25-1

PubChem CID

121225724

DrugBank

DBSALT002800

ChemSpider

58902513

UNII

1PVF6JLU7B

KEGG

D10939

ChEMBL

ChEMBL3707243

Chemical and physical data3D model (JSmol)

Interactive image

SMILES

O.Cc1ccc(cc1)S(=O)(=O)[O-].C[N+]2(C)CC[C@@H](C2)OC(=O)[C@@](O)(C3CCCC3)c4ccccc4

InChI

InChI=1S/C19H28NO3.C7H8O3S.H2O/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;1-6-2-4-7(5-3-6)11(8,9)10;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;2-5H,1H3,(H,8,9,10);1H2/q+1;;/p-1/t17-,19-;;/m0../s1
Key:UOWOLENSDISMPG-FFUVTKDNSA-M

Glycopyrronium tosylate, sold under the brand name Qbrexza among others, is a medication used for the treatment of primary axillary hyperhidrosis.^[1]^[2]^[3]

It was approved for medical use in the United States in June 2018,^[4] and in Japan in January 2022.^[5]

References

^ ^a ^b "Qbrexza- glycopyrronium cloth". DailyMed. 17 January 2022. Retrieved 2 November 2022.
^ Nwannunu CE, Limmer AL, Coleman K, Shah R, Patel RR, Mui UN, Tyring SK (March 2019). "Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis". Skin Therapy Letter. 24 (2): 1–3. PMID 30970203.
^ Lamb YN (November 2019). "Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use". Clinical Drug Investigation. 39 (11): 1141–1147. doi:10.1007/s40261-019-00853-x. PMC 6877702. PMID 31571127.
^ "Drug Approval Package: Qbrexza (glycopyrronium)". U.S. Food and Drug Administration (FDA). 20 November 2018. Retrieved 1 November 2022.
^ "Maruho Launches Primary Axillary Hyperhidrosis Treatment". Maruho. 23 May 2022. Retrieved 2 November 2022.